Literature DB >> 26935287

Prevalence and determinants of resistant hypertension in a sample of patients followed in Italian hypertension centers: results from the MINISAL-SIIA study program.

F Galletti1, A Barbato1.   

Abstract

The aim of this study was to detect the prevalence of resistant hypertension (RH), allowing for adherence to appropriate lifestyle measures according to European Society of Hypertension-European Society of Cardiology (ESH-ESC) 2013 guidelines, in a sample of 1284 hypertensive subjects participating at the MINISAL-SIIA study. Hypertensive patients were recruited in 47 Italian centres, recognised by the Italian Society of Hypertension. Anthropometric indexes, blood pressure and 24-h urinary sodium (Na24h) and potassium (K24h) excretion were measured. Data on antihypertensive therapy were available for 1177 (92%) subjects. The population was divided into three groups (North, Central and South), according to their geographical location. Accounting only at the treatment criteria, the prevalence of RH was 8.2% (96/1177). RH prevalence in the southern, central and northern regions was respectively: 1, 3.8 and 3.3% (P<0.001). Participants with RH were older and showed a higher body mass index (BMI) and waist circumference compared with other subjects (P<0.005). RH risk was statistically significant (P<0.01) increased of 1.52-fold (95% confidence interval (CI):1.20-1.92) for one unit increase in s.d. score of age (11 years), and 1.50-fold (95% CI:1.22-1.83) for one unit increase in s.d. score of BMI (4.5 kg m-2). Including in RH diagnosis also the adherence to appropriate lifestyle measures, such as dietary salt restriction (Na24h <100 mmol) and normal BMI (18-25 kg m-2), RH prevalence felt respectively to 2.2% (26/1177) and 0.8% (9/1177). In conclusion in this national sample of Italian hypertensive population, among participants following both drug treatment and lifestyle modifications advises, the 'true' RH prevalence appears to be particularly low.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26935287     DOI: 10.1038/jhh.2016.6

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  19 in total

Review 1.  Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations.

Authors:  Dmitrij Achelrod; Ulrich Wenzel; Simon Frey
Journal:  Am J Hypertens       Date:  2014-08-25       Impact factor: 2.689

2.  Salt and cardiovascular disease.

Authors:  Francesco P Cappuccio
Journal:  BMJ       Date:  2007-04-28

3.  Predictors of resistant hypertension in an unselected sample of an adult male population in Italy.

Authors:  Antonio Barbato; Ferruccio Galletti; Roberto Iacone; Francesco P Cappuccio; Giovanni Rossi; Renato Ippolito; Antonella Venezia; Eduardo Farinaro; Pasquale Strazzullo
Journal:  Intern Emerg Med       Date:  2011-03-10       Impact factor: 3.397

4.  Artefacts in measurement of blood pressure and lack of target organ involvement in the assessment of patients with treatment-resistant hypertension.

Authors:  A D Mejia; B M Egan; N J Schork; A J Zweifler
Journal:  Ann Intern Med       Date:  1990-02-15       Impact factor: 25.391

5.  Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Circulation       Date:  2008-06-24       Impact factor: 29.690

6.  2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension.

Authors: 
Journal:  J Hypertens       Date:  2013-10       Impact factor: 4.844

Review 7.  A comprehensive review on salt and health and current experience of worldwide salt reduction programmes.

Authors:  F J He; G A MacGregor
Journal:  J Hum Hypertens       Date:  2008-12-25       Impact factor: 3.012

8.  Clinical management of resistant hypertension: practical recommendations from the Italian Society of Hypertension (SIIA).

Authors:  Franco Veglio; Guido Grassi; Giuseppe Mancia; Massimo Volpe
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-08-15

9.  2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mansia; Guy De Backer; Anna Dominiczak; Renata Cifkova; Robert Fagard; Giuseppe Germano; Guido Grassi; Anthony M Heagerty; Sverre E Kjeldsen; Stephane Laurent; Krzysztof Narkiewicz; Luis Ruilope; Andrzej Rynkiewicz; Roland E Schmieder; Harry A Struijker Boudier; Alberto Zanchetti
Journal:  Blood Press       Date:  2007       Impact factor: 2.835

Review 10.  State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension.

Authors:  Pantelis A Sarafidis; George L Bakris
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-02       Impact factor: 3.738

View more
  3 in total

Review 1.  Resistant Hypertension: An Incurable Disease or Just a Challenge For Our Medical Skill?

Authors:  Marina Di Pilla; Rosa Maria Bruno; Stefano Taddei
Journal:  High Blood Press Cardiovasc Prev       Date:  2016-05-17

2.  Refractory hypertension focus on nighttime blood pressure and nondipping.

Authors:  Cesare Cuspidi; Marijana Tadic; Guido Grassi
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-02-13       Impact factor: 3.738

3.  Consensus paper on the evaluation and treatment of resistant hypertension by the Turkish Society of Cardiology.

Authors:  Asife Sahinarslan; Emine Gazi; Meryem Aktoz; Cigdem Ozkan; Gülay Ulusal Okyay; Ozgul Ucar Elalmis; Erdal Belen; Reviewers Atila Bitigen; Ulver Derici; Neslihan Bascil Tutuncu; Aylin Yildirir
Journal:  Anatol J Cardiol       Date:  2020-09       Impact factor: 1.596

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.